MONTREAL, Dec. 1, 2022
/CNW/ - AbbVie (NYSE: ABBV), today announced that RINVOQ is
now listed as a special authorization medication or exception
medication status on the formularies of Alberta1, New Brunswick2, Ontario3, Quebec4 and Saskatchewan5 for the treatment of
adults with rheumatoid arthritis (RA) and psoriatic arthritis
(PsA). In addition, RINVOQ is now listed as a Limited Use product
on the formulary of the Non-Insured Health Benefits program
(NIHB)6 for the treatment of RA and PsA.
Information regarding the specific reimbursement criteria for
each province and jurisdiction may be found by consulting the links
below:
- Alberta Health – Drug Benefit List
- Government of New Brunswick –
Drug Plans Formulary
- Ontario Ministry of Health – Ontario Drug Benefit
Formulary
- Régie de l'assurance maladie du Québec – List of
Medications
- Government of Saskatchewan –
Saskatchewan Drug formulary
- Non-Insured Health Benefits program – Drug Benefit List
This announcement comes two months after AbbVie successfully
reached an agreement with the pan-Canadian Pharmaceutical Alliance
(pCPA), bringing a new treatment option to patients living with RA
and PsA.
Rheumatoid arthritis (RA) is a chronic, progressive autoimmune
disease that can affect multiple joints in the body and lead to
pain, stiffness and swelling.7 RA affects about one in
100 Canadians, which is approximately 300,000 people.7
Psoriatic arthritis (PsA) is a type of inflammatory arthritis
that usually appears in people living with psoriasis.8
Between 10 and 30% of people with psoriasis will develop PsA, which
can cause swelling, pain and inflammation in the
joints.8
About
RINVOQ® (upadacitinib)9
RINVOQ is a once-daily oral medication in an extended-release
tablet. It is a Janus kinase (JAK) inhibitor that interferes with
the JAK-STAT signaling pathway, which is thought to play a role in
inflammatory response.
RINVOQ is indicated for the treatment of adults with moderately
to severely active rheumatoid arthritis (RA) who have had an
inadequate response or intolerance to methotrexate, for adults with
active psoriatic arthritis (PsA) who have had an inadequate
response or intolerance to methotrexate or other DMARDs, for
adults and adolescents 12 years of age and older with refractory
moderate to severe atopic dermatitis (AD) who are not adequately
controlled with a systemic treatment or when use of those therapies
is inadvisable, and for adults with active ankylosing spondylitis
(AS) who have had an inadequate response to a biologic DMARD or
when use of those therapies is inadvisable.
For important therapeutic and safety information, please consult
the RINVOQ Product Monograph at www.abbvie.ca.
About AbbVie in
Rheumatology
For more than 20 years, AbbVie has been dedicated to improving
care for people living with rheumatic diseases. Anchored by a
longstanding commitment to discovering and delivering
transformative therapies, we pursue cutting-edge science to help
improve our understanding of promising new pathways and targets, as
we ultimately hope to help more people living with rheumatic
diseases to reach their treatment goals.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
that solve serious health issues today and address the medical
challenges of tomorrow. We strive to have a remarkable impact on
people's lives across several key therapeutic areas: immunology,
oncology, neuroscience, eye care, virology, women's health and
gastroenterology, in addition to products and services across our
Allergan Aesthetics portfolio. For more information about AbbVie,
please visit us at www.abbvie.ca. Follow AbbVie Canada on Twitter,
on Instagram, or find us on LinkedIn.
References
__________________________
|
1 Alberta
Health.
https://idbl.ab.bluecross.ca/idbl/drugDetails?_cid=ebdeaaaa-9331-4bcc-a6d8-ac0d0518c373&id=0000092897&intchg_grp_nbr=1&detailId=7618569.
Accessed November 18, 2022.
|
2 New
Brunswick Drug Plans
Formulary. http://www.gnb.ca/0212/BenefitUpdates-e.asp.
Accessed November 22, 2022.
|
3 Ontario
Ministry of Health.
https://www.formulary.health.gov.on.ca/formulary/ Accessed November
18, 2022.
|
4 Régie de
l'assurance maladie de Québec.
https://www.ramq.gouv.qc.ca/fr/a-propos/liste-medicaments Accessed
November 22, 2022.
|
5 Government
of Saskatchewan.
https://formulary.drugplan.ehealthsask.ca/SearchFormulary/BG/799398
Accessed November 18, 2022.
|
6
Non-Insured Health Benefits Program.
https://nihb-ssna.express-scripts.ca/en/0205140506092019/16/160407.
Accessed November 10, 2022.
|
7 Arthritis
Society of Canada.
https://arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/rheumatoid-arthritis
Accessed November 2, 2022.
|
8 Arthritis
Society of Canada.
https://arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/psoriatic-arthritis.
Accessed November 2, 2022.
|
9 AbbVie
Corporation.
https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/RINVOQ_PM_EN.pdf.
Accessed November 2, 2022.
|
SOURCE AbbVie Canada